Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Tax Provisions (2021 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Tax Provisions for 5 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 173.56% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Dec 2025, up 21.74% year-over-year, with the annual reading at $56.4 million for FY2025, 21.74% up from the prior year.
  • Tax Provisions hit $18.3 million in Q4 2025 for Harmony Biosciences Holdings, up from $16.6 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $26.5 million in Q4 2023 to a low of -$80.0 million in Q3 2022.
  • Historically, Tax Provisions has averaged $4.6 million across 5 years, with a median of $9.8 million in 2023.
  • Biggest five-year swings in Tax Provisions: plummeted 8766.52% in 2022 and later soared 701.48% in 2023.
  • Year by year, Tax Provisions stood at $1.8 million in 2021, then crashed by 350.2% to -$4.4 million in 2022, then skyrocketed by 701.48% to $26.5 million in 2023, then tumbled by 74.79% to $6.7 million in 2024, then soared by 173.56% to $18.3 million in 2025.
  • Business Quant data shows Tax Provisions for HRMY at $18.3 million in Q4 2025, $16.6 million in Q3 2025, and $9.9 million in Q2 2025.